Standout Papers

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI The... 2010 2026 2015 2020 1.9k
  1. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers (2013)
    Helena A. Yu, Maria E. Arcila et al. Clinical Cancer Research
  2. HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation (2012)
    Ken Takezawa, Valentina Pirazzoli et al. Cancer Discovery
  3. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes (2017)
    Catherine C. Coombs, Ahmet Zehir et al. Cell stem cell
  4. Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations (2011)
    Paul K. Paik, Maria E. Arcila et al. Journal of Clinical Oncology
  5. Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation (2010)
    Geoffrey R. Oxnard, Maria E. Arcila et al. Clinical Cancer Research
  6. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay (2011)
    Maria E. Arcila, Geoffrey R. Oxnard et al. Clinical Cancer Research
  7. ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer (2013)
    Justin F. Gainor, Anna M. Varghese et al. Clinical Cancer Research
  8. Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels (2017)
    Lawrence J. Jennings, Maria E. Arcila et al. Journal of Molecular Diagnostics
  9. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions (2017)
    Jaclyn F. Hechtman, Ryma Benayed et al. The American Journal of Surgical Pathology
  10. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial (2016)
    Alexander Drilon, Natasha Rekhtman et al. The Lancet Oncology
  11. High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden (2019)
    Ryma Benayed, Michael Offin et al. Clinical Cancer Research

Immediate Impact

1 by Nobel laureates 8 from Science/Nature 139 standout
Sub-graph 1 of 13

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers
2022 Standout
2 intermediate papers

Works of Maria E. Arcila being referenced

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non–Small Cell Lung Cancer
2017
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
2013 Standout
and 6 more

Author Peers

Author Last Decade Papers Cites
Maria E. Arcila 10412 8528 4633 5635 248 15.3k
Marileila Varella‐Garcia 10913 9895 3936 7049 241 17.8k
Neal I. Lindeman 12979 11485 5703 7938 166 21.9k
Frank G. Haluska 7860 10762 2979 7810 138 18.5k
Christine Chevreau 9987 6054 3788 6252 308 15.3k
Brian Schwartz 5784 5154 3332 7652 143 14.2k
Sai‐Hong Ignatius Ou 13702 11488 3407 5401 345 17.1k
Beow Y. Yeap 10059 6993 2128 3028 203 14.1k
Fairooz F. Kabbinavar 8593 12727 4023 7654 174 21.4k
Michael F. Berger 4928 7601 4999 7242 317 16.7k
Vera Hirsh 13967 14466 2752 4798 196 19.4k

All Works

Loading papers...

Rankless by CCL
2026